Fig. 2: Synergy therapy delays tumor growth through increasing CD8 + CAR-T In Vivo.
From: Systemic tumor regression with synergy therapy: radiotherapy and CAR-T
A NCG mice were injected CLDN18.2 panc02 subcutaneously on the right side. Seven days later, the mice were separated to 4 groups (n = 4), two groups were randomly selected to treat with 4 Gy local radiotherapy, on the 14th day, and the mice were intravenous injected with control T cells or CLDN18.2 CAR-T cells. B The tumor volumes were recorded every two days and analyses using the formula \(\pi \div6\times H\times W\times L\), multiple comparisons were performed with two-way ANOVA. C Tumors of mice were assessed at the time of necropsy with representative macroscopic images, and (D) the tumor weight was measured. E Murine peripheral blood was drawn at 7, 14, 18 days after indicated CAR-T cell infusion to determine the CAR-T cell counts. Data indicate the mean number of T cells per 10 μl of blood as measured by flow cytometry. Evaluation of CD8 + CAR-T (F) and effector CAR-T cell percentage (G) 7 days post CAR-T injection. Data in (D–G) were calculated by two-tailed Student’s t test. presented as the mean ± SD, n = 4. *p < 0.05, **p < 0.01, ***p < 0.001.
